Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Ravikumar Peri

Showing results (1-10 of 8) with videos related to

Pageof 1
Sort By:
Future Medicinal Chemistry|March 24, 2011
Screening technologies for ion channel drug discoveryGeorg C Terstappen, Renza Roncarati, John Dunlop, et al.
Expert Opinion on Drug Discovery|March 20, 2013
Functional screening of α7 nicotinic receptor ligandsJohn Dunlop, Ravikumar Peri, Georg C Terstappen, et al.
Nature Reviews. Drug Discovery|March 22, 2008
High-throughput electrophysiology: an emerging paradigm for ion-channel screening and physiologyJohn Dunlop, Mark Bowlby, Ravikumar Peri, et al.
Combinatorial Chemistry & High Throughput Screening|August 13, 2008
Ion channel screeningJohn Dunlop, Mark Bowlby, Ravikumar Peri, et al.
Assay and Drug Development Technologies|November 20, 2009
Development of an improved IP(1) assay for the characterization of 5-HT(2C) receptor ligandsJean Y Zhang, Dianne M Kowal, Stanley P Nawoschik, et al.
Nature Reviews. Drug Discovery|June 17, 2024
Author Correction: The state of the art in secondary pharmacology and its impact on the safety of new medicinesRichard J Brennan, Stephen Jenkinson, Andrew Brown, et al.
Nature Reviews. Drug Discovery|May 21, 2024
The state of the art in secondary pharmacology and its impact on the safety of new medicinesRichard J Brennan, Stephen Jenkinson, Andrew Brown, et al.
Clinical Pharmacology and Therapeutics|September 1, 2020
Time for a Fully Integrated Nonclinical-Clinical Risk Assessment to Streamline QT Prolongation Liability Determinations: A Pharma Industry PerspectiveHugo M Vargas, Michael G Rolf, Todd A Wisialowski, et al.
Pageof 1

Showing results (1-10 of 8) with videos related to

Sort By:
Pageof 1
Future Medicinal Chemistry|March 24, 2011
Screening technologies for ion channel drug discoveryGeorg C Terstappen, Renza Roncarati, John Dunlop, et al.
Expert Opinion on Drug Discovery|March 20, 2013
Functional screening of α7 nicotinic receptor ligandsJohn Dunlop, Ravikumar Peri, Georg C Terstappen, et al.
Nature Reviews. Drug Discovery|March 22, 2008
High-throughput electrophysiology: an emerging paradigm for ion-channel screening and physiologyJohn Dunlop, Mark Bowlby, Ravikumar Peri, et al.
Combinatorial Chemistry & High Throughput Screening|August 13, 2008
Ion channel screeningJohn Dunlop, Mark Bowlby, Ravikumar Peri, et al.
Assay and Drug Development Technologies|November 20, 2009
Development of an improved IP(1) assay for the characterization of 5-HT(2C) receptor ligandsJean Y Zhang, Dianne M Kowal, Stanley P Nawoschik, et al.
Nature Reviews. Drug Discovery|June 17, 2024
Author Correction: The state of the art in secondary pharmacology and its impact on the safety of new medicinesRichard J Brennan, Stephen Jenkinson, Andrew Brown, et al.
Nature Reviews. Drug Discovery|May 21, 2024
The state of the art in secondary pharmacology and its impact on the safety of new medicinesRichard J Brennan, Stephen Jenkinson, Andrew Brown, et al.
Clinical Pharmacology and Therapeutics|September 1, 2020
Time for a Fully Integrated Nonclinical-Clinical Risk Assessment to Streamline QT Prolongation Liability Determinations: A Pharma Industry PerspectiveHugo M Vargas, Michael G Rolf, Todd A Wisialowski, et al.
Pageof 1